Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.

One way to make lemonade from lemons in a broad stock-market pullback is to weed out the losers from an investment portfolio, harvesting tax-loss carryforwards along the way. These losses can be used to offset future capital gains that may be generated when the stock market once again is in an uptrend. It takes discipline to sell stocks, however. Many times, investors are reluctant to sell stocks that are down in the dumps due to hopes that a turnaround is coming. In this case, an alternative strategy can be to sell losers and buy a similar stock or related industry ETF in an attempt to capture upside down the road. But beware of the tax rules. The so-called wash-sale rule from the IRS prohibits selling an investment for a loss and replacing it with the same or "substantially identical" investment 30 days before or after the sale. Here's a list of stocks on the Argus HOLD list that have fallen the farthest from their 52-week highs and could be tax-loss candidates.

This pick list highlights constituents of the Morningstar US Mid Cap Index that we believe offer investors the best risk-adjusted return prospects. The market capitalization range for U.S. mid-caps typically falls between $1 billion and $8 billion and represents 20% of the total capitalization of the U.S. equity market.

Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.